Cancer biology and immunotherapy
3 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- WEIZMANN INSTITUTE OF SCIENCE
World-class Israeli research institute excelling in neuroscience, cancer biology, immunotherapy, and genomics through ERC-funded investigator-driven science.
“Concentrated recent work on cancer, melanoma, immunotherapy, and personalized drug screening (Cancer-Drug-Screen, COMbAT, plus 5 recent cancer-keyword projects).”
PrimaryIL214 projects - KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
TU Munich's university hospital: translational research in oncology, neuroscience, and precision diagnostics with strong ERC track record and advanced imaging capabilities.
“Projects like PanCaT (pancreatic cancer models), BCM-UPS (B-cell malignancies), EXODUS (immune cell labeling), and DSMT16 (intestinal cancer inflammation) demonstrate deep oncology expertise across multiple cancer types.”
PrimaryDE49 projects - DE DUVE INSTITUTE AISBL
Brussels biomedical research institute specializing in cancer immunotherapy, vascular disease genetics, gene therapy, and 3D tissue bioprinting.
“Core contributor across MESI-STRAT (breast cancer metabolism), IMMUcan (immunoprofiling of cancer cohorts), INCITE (immune niches for immunotherapy), and V.A. Cure (somatic mutations).”
PrimaryBE6 projects